Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Oct 7, 2020- Data show ID NOW performance of 95.0% sensitivity and 97.9% specificity within seven days of symptom onset- ID NOW is the most studied COVID-19 test available; interim post-authorization study evaluated 1,003 people- To date, Abbott has shipped more than 12 million ID NOW tests to all 50 states and provided more than 30 million rapid and lab-based COVID-19 tests in the U.S. since March-
Sep 30, 2020- Low back pain affects one in 10 Americans and often impacts the patient physically, emotionally and economically- The multicenter, randomized, controlled DISTINCT study represents an Abbott collaboration with both spine surgeons and pain specialists to amass post-market evidence for its BurstDR™ spinal cord stimulation therapy for patients who have limited surgical options
Sep 28, 2020- The FreeStyle Libre 3 system automatically delivers real-time, up-to-the-minute glucose readings, unsurpassed 14-day accuracy[1] and optional glucose alarms directly to smartphones[2] for people with diabetes- With the smallest and thinnest[3] wearable glucose sensor (about the size of two stacked U.S. pennies), FreeStyle Libre 3 users can view their glucose levels discreetly[4] and conveniently,[5] anytime[6]- Building on the proven FreeStyle Libre 2 sensor performance with a new sensor design at the same affordable price as previous versions,[7] the FreeStyle Libre 3 system is the latest innovation of Abbott's world-leading[8] continuous glucose monitoring technology- Sep 21, 2020- CE Mark for MitraClip G4 offers physicians an innovative next-generation system with more options for mitral valve repair using proven clip-based technology- MitraClip is a first-of-its-kind transcatheter mitral valve therapy, now on its fourth generation, improving further on MitraClip's history as a safe and effective treatment option